ATM rs11212617: Understanding Metformin Response Associations
The rs11212617 variant is a single nucleotide polymorphism located within the ATM gene. It has been studied for its potential association with how individuals with type 2 diabetes respond to the medication metformin.
What each genotype means
Typical metformin response
This genotype represents the common baseline for this variant. Research into whether this specific genetic profile influences how your body responds to metformin has yielded mixed results, with some studies suggesting no significant difference in glycemic control compared to other genotypes. Please discuss your diabetes management and medication dosing with your clinician or pharmacist.
Carried by approximately 30-35% of people of European ancestry.
Potential metformin response variation
Some early research suggested that carrying the C allele might be associated with a better glycemic response to metformin, though subsequent large-scale studies have not consistently confirmed this effect. Because the evidence is limited and conflicting, this genotype should not be used to guide clinical decisions. Please consult your healthcare provider regarding your specific treatment plan.
Carried by approximately 45-50% of people of European ancestry.
Potential metformin response variation
While some initial studies linked the C allele to improved metformin efficacy, later clinical trials, such as the Diabetes Prevention Program, found that this association was not robust or reproducible. The clinical significance of this genotype remains uncertain and is not currently used to predict how well you will respond to metformin. Always discuss your medication efficacy and any concerns with your doctor.
Carried by approximately 15-20% of people of European ancestry.
What is rs11212617?
The variant rs11212617 is a specific change in the DNA sequence located in an intronic region of the ATM gene. In genetics, an intronic variant sits within a non-coding section of a gene, meaning it does not directly provide instructions for building a protein. Instead, such variants may influence how a gene is regulated or expressed. Researchers identify this variant by its rsID (reference SNP cluster ID), which acts as a unique identifier in genomic databases. Because it is located within the ATM gene, scientists have investigated whether this specific location might influence biological pathways relevant to metabolic health and drug response.
The Role of the ATM Gene
The ATM gene provides instructions for making a protein called ataxia-telangiectasia mutated. This protein is primarily known for its critical role in DNA repair and maintaining genomic stability by sensing DNA damage and signaling the cell to pause its cycle for repairs. Beyond its role in DNA maintenance, research has suggested that the ATM protein may also be involved in cellular energy metabolism. Specifically, some studies have explored whether ATM interacts with pathways that regulate AMP-activated protein kinase (AMPK), a key sensor of cellular energy status that is also a target of the drug metformin. This potential link between DNA repair machinery and metabolic regulation is why the ATM gene has become a subject of interest in pharmacogenomics.
Research on Metformin Response
The association between rs11212617 and metformin response is a subject of ongoing scientific debate. Early genome-wide association studies suggested that the C allele of this variant might be linked to improved glycemic response in patients taking metformin for type 2 diabetes. However, the evidence is inconsistent. While some cohorts have reported a statistically significant association with better treatment outcomes, other large-scale studies, such as those conducted within the Diabetes Prevention Program, failed to replicate these findings. Furthermore, some studies have found no significant association in specific populations. These conflicting results highlight the complexity of drug response, which is likely influenced by a combination of genetic factors, lifestyle, diet, and other environmental variables rather than a single genetic variant.
Population Frequency
The rs11212617 variant is relatively common in many populations. In European populations, the minor allele frequency (the C allele) is typically observed between 40% and 45%. Because this variant is common, a large portion of the population carries at least one copy of the C allele. Frequency can vary across different ancestral groups, and researchers often account for these differences when conducting genetic studies to ensure that findings are not skewed by population structure.
Interpreting Genetic Information
It is important to understand that genetic variants like rs11212617 are not diagnostic tools. The current scientific evidence regarding this variant is limited and inconsistent, meaning it cannot be used to predict how an individual will respond to metformin. If you are living with type 2 diabetes and have questions about your medication, it is essential to consult with your healthcare provider or a clinical pharmacist. They are the only professionals qualified to evaluate your specific health history, current treatment plan, and clinical needs. Never make changes to your prescribed medication regimen based on genetic test results without professional medical guidance.
How common is this variant?
The minor allele (C) of rs11212617 has a frequency of approximately 0.40 to 0.45 in European populations, making it a common genetic variant.
Frequently asked questions
Can I use rs11212617 to predict if metformin will work for me?
No. The scientific evidence linking this variant to metformin response is inconsistent and not strong enough to be used for clinical decision-making or predicting individual drug efficacy.
Is rs11212617 a diagnostic test for diabetes?
No. This variant is not used to diagnose type 2 diabetes. It is a research-level marker that has been studied in the context of pharmacogenomics, not disease diagnosis.
Should I change my metformin dose based on my genotype?
Absolutely not. You should never alter your medication dosage or stop taking your medication based on genetic test results. Always discuss your treatment plan with your doctor.
Why do different studies show different results for this variant?
Genetic associations are complex and can be influenced by differences in study design, population ancestry, sample size, and environmental factors. Inconsistent results are common in pharmacogenomic research.
Sources & further reading
Educational information only, last refreshed 10/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11212617?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ATM
Missense variant (p.Asp1853Asn) in ATM associated with altered DNA damage response, radiation-induced toxicity, and chemotherapeutic sensitivity.
This variant in the ATM gene is a clinically significant marker often studied in the context of DNA repair and cancer susceptibility.
This variant in the ATM gene is one of several SNPs identified as contributing to a cumulative increased risk for breast cancer.
This variant in the ATM gene is one of several identified as contributing to minor, independent risks for specific health conditions.